5:29 PM
 | 
Dec 13, 2013
 |  BC Extra  |  Clinical News

Aveo slips on tivozanib update in colorectal cancer

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) said a planned interim analysis of the Phase II BATON-CRC trial showed first-line treatment with tivozanib plus chemotherapy is unlikely to meet the primary endpoint of improving progression-free survival (PFS) vs. Avastin bevacizumab plus chemotherapy to treat metastatic colorectal cancer (mCRC). The news...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >